272 related articles for article (PubMed ID: 18581828)
1. Is unfractionated heparin equivalent to low-molecular-weight heparin for venous thromboembolism?
Graber MA; Dachs R; Darby-Stewart A
Am Fam Physician; 2008 Jun; 77(11):1492-3. PubMed ID: 18581828
[No Abstract] [Full Text] [Related]
2. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
[TBL] [Abstract][Full Text] [Related]
3. Guideline update. VTE disease: which agents, and when.
Holten KB; Merok J
J Fam Pract; 2009 Mar; 58(3):E1. PubMed ID: 19284934
[No Abstract] [Full Text] [Related]
4. The emerging role of low-molecular-weight heparin in cardiovascular medicine.
Hirsh J; Bates SM
Prog Cardiovasc Dis; 2000; 42(4):235-46. PubMed ID: 10661777
[TBL] [Abstract][Full Text] [Related]
5. [The treatment of deep venous thrombosis with low-molecular-weight heparin].
Samama MM; Achkar A; Horellou MH
Rev Med Brux; 1995; 16(4):304-9. PubMed ID: 7481248
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
7. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.
Tebbe U; Schellong SM; Haas S; Gerlach HE; Abletshauser C; Sieder C; Bramlage P; Riess H
Am Heart J; 2011 Feb; 161(2):322-8. PubMed ID: 21315215
[TBL] [Abstract][Full Text] [Related]
8. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
9. [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?].
Scharf RE
Dtsch Med Wochenschr; 2011 Nov; 136(47):2403. PubMed ID: 22094968
[No Abstract] [Full Text] [Related]
10. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
Martínez-González J; Vila L; Rodríguez C
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review.
Duhl AJ
J Reprod Med; 2008 Sep; 53(9):657-66. PubMed ID: 18839817
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic therapy and survival in cancer patients.
Kakkar AK
Best Pract Res Clin Haematol; 2009 Mar; 22(1):147-51. PubMed ID: 19285281
[TBL] [Abstract][Full Text] [Related]
13. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2. Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease.
Munro A; English C
Emerg Med J; 2008 May; 25(5):287-9. PubMed ID: 18434466
[No Abstract] [Full Text] [Related]
14. Anticoagulation quality and the risk of recurrence of venous thromboembolism.
Poli D; Antonucci E; Ciuti G; Abbate R; Prisco D
Thromb Haemost; 2007 Nov; 98(5):1148-50. PubMed ID: 18000626
[No Abstract] [Full Text] [Related]
15. Treatment of venous thrombosis.
Lee AY
Cancer Treat Res; 2009; 148():243-57. PubMed ID: 19377928
[No Abstract] [Full Text] [Related]
16. The optimal long-term treatment of venous thromboembolism.
Prandoni P
Clin Adv Hematol Oncol; 2004 Nov; 2(11):729-32. PubMed ID: 16170889
[No Abstract] [Full Text] [Related]
17. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.
Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD
Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560
[TBL] [Abstract][Full Text] [Related]
18. The status of new anticoagulants.
Bates SM; Weitz JI
Br J Haematol; 2006 Jul; 134(1):3-19. PubMed ID: 16803562
[TBL] [Abstract][Full Text] [Related]
19. Prevention of venous thromboembolism after ischemic stroke.
Kase CS; Pineo GF
Curr Opin Pulm Med; 2008 Sep; 14(5):389-96. PubMed ID: 18664967
[TBL] [Abstract][Full Text] [Related]
20. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
Rhodes S; Bond S
Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
